Pituitary tumors

Research output: Contribution to journalReview articlepeer-review

Abstract

Pituitary adenomas are the most common intrasellar tumors. With the exception of prolactinomas, first-line treatment is almost always surgical. Prolactinomas are usually treated with dopamine agonists such as cabergoline or bromocriptine. Somatostatin analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used as primary therapy in selected cases. Pegvisomant, a growth hormone receptor antagonist, is reserved for acromegalic patients who are resistant to treatment with somatostatin analogues. No effective medical therapy is available for adenomas that secrete adrenocorticotropic hormone, and occasionally bilateral adrenalectomy is required to resolve severe hypercortisolemia. Radiation therapy (fractionated or radiosurgery) can be used for residual or recurrent pituitary tumors. Asymptomatic, nonfunctioning pituitary adenomas may be followed without any intervention, but surgery is typically indicated if there are symptoms of mass effect on the optic chiasm or endocrine dysfunction. In the hands of an experienced pituitary neurosurgeon, the prognosis for endocrinologic recovery and visual improvement is good.

Original languageEnglish (US)
Pages (from-to)287-296
Number of pages10
JournalCurrent Treatment Options in Neurology
Volume11
Issue number4
DOIs
StatePublished - 2009

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pituitary tumors'. Together they form a unique fingerprint.

Cite this